AntriaBio

Scientific Advisory Board

About

Scientific Advisory Board

Robert B. Bhisitkul, M.D., Ph.D.

SAB Member

Dr. Bhisitkul is a Professor of Clinical Ophthalmology and retinal specialist at the University of California, San Francisco School of Medicine's Department of Ophthalmology. He earned his M.D. from Stanford University and Ph.D. in Neuroscience from Yale University. Dr. Bhisitkul completed his residency and fellowship training at the Massachusetts Eye and Ear Infirmary and Harvard Medical School. In his 20 years of experience as a retinal surgeon and clinical scientist, Dr. Bhisitkul has been an investigator in 15 randomized clinical trials of novel therapies for retinal diseases, including anti-VEGF therapies for DME, and served as Clinical Trial Director for the SEVEN-UP Study, the first longitudinal trial to determine long-term vision outcomes for macular degeneration patients undergoing multi-year anti-VEGF therapy. His laboratory research focuses on basic mechanisms of retinal diseases in animal models and cell culture, as well as new technologies for retinal surgery and treatments. Dr. Bhisitkul has served as a consultant and clinical advisor for numerous pharmaceutical companies including those with market-leading products for macular edema. Dr. Bhisitkul has served as Associate Editor and Web Editor of the British Journal of Ophthalmology and is an ad hoc reviewer for several journals including Ophthalmology, American Journal of Ophthalmology and IOVS.

Jerrold Olefsky, M.D.

SAB Member

Dr. Olefsky is Distinguished Professor of Medicine at the University of California, San Diego (UCSD) Division of Endocrinology and Metabolism and the Associate Dean of Scientific Affairs for the UCSD School of Medicine, and he is also a member of the Institute of Medicine and the American Academy of Arts and Sciences. One of his seminal contributions to the field of Medicine has been the identification of the role of insulin resistance as a primary cause of Type II (non-insulin dependent, adult-onset) diabetes, polycystic ovarian syndrome, and other human diseases. His work has also helped develop insulin-sensitizing drugs that are now standard therapies for Type II diabetes. More recently, his lab has developed studies establishing the role of macrophage-mediated tissue inflammation as a key cause of obesity-related insulin resistance. He has conducted numerous studies to help define the basic genetic and cellular mechanisms underlying decreased insulin action in human pathophysiologic states.